Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE (Tables)

FAIR VALUE (Tables)

3 Months Ended

Mar. 31, 2015

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

The following tables set forth the Company’s financial instruments carried at fair value using the lowest level of input applicable to each financial instrument as of March 31, 2015 and December 31, 2014:

	March 31, 2015
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
July 2010 Warrants	$	—	$	700	$	—	$	700
February 2013 Public Offering Warrants		—		—		1,039,500		1,039,500
August 2014 Warrants		—		3,848,464		—		3,848,464
Total	$	—	$	3,849,164	$	1,039,500	$	4,888,664

	December 31, 2014
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
July 2010 Warrants	$	—	$	999	$	—	$	999
February 2013 Public Offering Warrants		—		—		1,127,500		1,127,500
August 2014 Warrants		—		4,048,416		—		4,048,416
Total	$	—	$	4,049,415	$	1,127,500	$	5,176,915

Schedule Of Changes In Fair Value Warrants Classified Level Three [Table Text Block]

The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy.

	Three Months Ended March 31, 2015		Twelve Months Ended December 31, 2014
Beginning balance – Fair value	$	1,127,500	$	3,355,000
Gain on derivatives resulting from change in fair value		(88,000)		(2,227,500)
Ending balance – Fair value	$	1,039,500	$	1,127,500

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References + Details